期刊： EXPERT REVIEW OF HEMATOLOGY, 2022; 15 (10)
Background Pulmonary embolism (PE) is a leading cause of death in stroke patients and a severe health burden worldwide. There is a pressing need to un......
期刊： EXPERT REVIEW OF HEMATOLOGY, 2022; 15 (11)
Background Multiple myeloma (MM), a bone marrow-resident hematological malignancy of plasma cells, has remained largely incurable despite the recent a......
期刊： EXPERT REVIEW OF HEMATOLOGY, 2022; 15 (8)
Background: Acute myeloid leukemia (AML) is a hematologic malignancy with genetic alterations. RUNX1, which is an essential transcription factor for h......
期刊： EXPERT REVIEW OF HEMATOLOGY, 2022; 15 (3)
Background Nodal peripheral T cell lymphoma (PTCL) confers a dismal prognosis when treated with conventional chemotherapy. Autologous stem cell transp......
期刊： EXPERT REVIEW OF HEMATOLOGY, 2022; 15 (8)
Introduction Transfusions of blood and blood components have inherent risks and the ensuing adverse reactions. It is very important to understand the ......
期刊： EXPERT REVIEW OF HEMATOLOGY, 2022; 15 (7)
Objectives Acute myeloid leukemia (AML) is a hematological malignancy with highly clinical heterogeneity resulting in poor outcomes. We aim to identif......
期刊： EXPERT REVIEW OF HEMATOLOGY, 2022; 15 (9)
Introduction Allogeneic hematopoietic stem cell transplantation (allo-HSCT), including human leukocyte antigen-matched sibling donor transplantation a......
期刊： EXPERT REVIEW OF HEMATOLOGY, 2022; 15 (5)
Introduction Hemophilia A (HA) or B (HB) is an X-linked recessive disorder caused by a defect in the factor VIII (FVIII) or factor IX (FIX) gene which......
期刊： EXPERT REVIEW OF HEMATOLOGY, 2022; 15 (4)
Background The QUAZAR AML-001 trial (NCT01757535) showed survival benefits with the maintenance treatment of oral azacitidine(CC-486) for acute myeloi......
期刊： EXPERT REVIEW OF HEMATOLOGY, 2022; 15 (4)
Background: Extramedullary myeloma has a more aggressive clinical course and inferior prognosis. Two types of extramedullary myeloma, paraosseous (PO)......
期刊： EXPERT REVIEW OF HEMATOLOGY, 2022; 15 (5)
Background Relapse is the leading cause of death from myeloid malignancies after allogeneic hematopoietic stem cell transplantation (HSCT). Azacitidin......
期刊： EXPERT REVIEW OF HEMATOLOGY, 2022; 15 (12)
Background Circular RNA (circRNA) regulates the pathogenesis of acute myeloid leukemia (AML). However, the mechanism of circRNA protein tyrosine kinas......
期刊： EXPERT REVIEW OF HEMATOLOGY, 2021; 14 (7)
Backgrounds Diffuse large B-cell lymphoma (DLBCL) is a common curable non-Hodgkin's lymphoma. Patients with this disease can be cured after the R-CHOP......
期刊： EXPERT REVIEW OF HEMATOLOGY, 2021; 14 (5)
Background: No clear clinical guidelines exist on anticoagulant use for chronic kidney disease (CKD) patients. We compared the efficacy and safety of ......
期刊： EXPERT REVIEW OF HEMATOLOGY, 2021; 14 (9)
Background: Relapsed/refractory (R/R) classical HL (cHL) and systemic anaplastic large-cell lymphoma (sALCL) treatment options are limited in China. T......
